Your session is about to expire
← Back to Search
Treatment for Von Willebrand Disease
N/A
Waitlist Available
Led By Robert Sidonio, MD
Research Sponsored by American Thrombosis and Hemostasis Network
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights
Summary
ATHN 9 is a natural history study to assess the safety of various Von Willebrand Factor (VWF) regimens for different indications (on-demand, surgery and prophylaxis) in adult and pediatric participants with clinically severe congenital VWD.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Reported adverse events from VWF regimens for different indications (on-demand, surgery, and prophylaxis) as measured by EUHASS.
Secondary outcome measures
Analyze the effectivness of VWD treatment as measured by score on PROMIS questionnaire using the 7 PROMIS domains (depression; anxiety; physical function; pain; fatigue; sleep disturbance; and participation in social roles and activities).
Calculate the effectiveness of VWD treatment as measured by health care utilization.
Calculate the success of VWD treatment as measured by health care utilization.
+9 moreFind a Location
Who is running the clinical trial?
TakedaIndustry Sponsor
1,227 Previous Clinical Trials
4,222,397 Total Patients Enrolled
American Thrombosis and Hemostasis NetworkLead Sponsor
9 Previous Clinical Trials
4,385 Total Patients Enrolled
Robert Sidonio, MDPrincipal InvestigatorEmory University / Children's Healthcare of Atlanta
2 Previous Clinical Trials
20 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger